Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

agro-alliance (australia) pty ltd - triasulfuron - water dispersible granule - triasulfuron urea-sulfonyl active 750.0 g/kg - herbicide - barley | barley - post emergence | oats | oats - post-emergence | triticale | wheat | wheat - post emergent | wheat - pre-emerge - african turnip weed | amsinckia | annual phalaris | annual ryegrass | australian crassula | ball mustard | black bindweed | burr medic | capeweed | chamomile or matricaria | common cotula or carrot weed | common peppercress | coreopsis | corn gromwell, ironweed or sheepweed | crassula | deadnettle | denseflower fumitory | hedge or wild mustard | hyssop loosestrife | indian hedge mustard | lesser swinecress or bittercress | london rocket | long fruited turnip | longhead poppy | medic | mexican poppy | new zealand spinach | paradoxa grass | paterson's curse | prickly lettuce | rough poppy | shepherd's purse | skeleton weed | slender celery | smallflower fumitory | soursob or oxalis - suppression | sowthistles | stagger weed | stemless thistle | three cornered jack or doublegee | turnip weed | variegated thistle | vetches | volunteer chickpea | volunteer faba bean | volunteer field pea | volunteer lupin | volunteer sunflower | ward's weed | wild radish - suppression | wild radish or radish weed | wild turnip | w

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

imtrade australia pty ltd - imazapic as the ammonium salt - soluble concentrate - imazapic as the ammonium salt imidazolinone active 240.0 g/l - herbicide - fallow or prior to seeding a crop | peanut | sugar cane (post-emergent) | sugar cane (pre-emergent) | implement-minimal disturba - awnless barnyard grass | barnyard or water grass | blackberry nightshade | blue billygoat weed | boggabri weed | button grass | caltrop or yellow vine | common sida | cowvine | crowsfoot grass | dwarf amaranth or boggabri weed | giant or black pigweed | glossy nightshade | green amaranth | green summer grass | guinea grass | ipomoea spp. | liverseed or urochloa grass | milkweed | mintweed | native millet | nutgrass | pigweed spp. | stink grass | summer grass | amaranthus mitchellii | annual pigweed | australian millet | barnyard grass | bellvine | bindy-eye | black nightshade | black pigweed | blowaway grass | blue salvia | blue top | bullhead | bull's head | caltrop burr | cathead | cat's-head | coast button grass | convolvulus | crab grass | dactyloctenium aegyptium | giant pigweed | goat's-head | green summergrass | liverseed grass | love grass | mexican fire plant | mint weed | munyeroo | paddy lucerne | paddy's lucerne | peachvine | portulaca oleracea | puncture vine | purslane | salvia lanceolata | sida

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

imtrade australia pty ltd - sulfosulfuron - water dispersible granule - sulfosulfuron urea active 750.0 g/kg - herbicide - triticale - post-emergence | triticale - pre-emergence | wheat - post emergent | wheat - pre-emergent | from 3 leaf to early til - amsinckia | annual or wimmera ryegrass | barley grass - suppression | brome grass - suppression | brome grass(bromus diandrus)-suppression | brome grass(bromus rigidus)-suppression | canary grass | fumitory | squirrel-tail fescue or silver grass | volunteer canola - see label for except | volunteer field pea | wild mustard (s. arvensis) - suppression | wild oat | wild oat - suppression | wild radish or radish weed | wild turnip | wireweed, knotweed or hogweed | annual phalaris | brassica campestris | brassica rapa ssp. sylvestris | brassica rapa var. sylvestris | brome fescue | charlock | except tolerant to group b her | fallopia aviculare | festuca bromoides | field pea | jointed charlock | not triazine tolerant cultivar | pink weed | radish (wild) | rat's tail fescue | rigid ryegrass | silvery grass | trianthema decandra | trianthema galericulata | white charlock | white weed | wild charlock | wild radish - cereals | wimmera ryegrass | zaleya decandra | zaleya galericulata

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

imtrade australia pty ltd - imazethapyr - water dispersible granule - imazethapyr ungrouped active 700.0 g/kg - herbicide - centrosema (cavalcade) - pre-emergence | chickpea pre-emergent | faba bean - pre-emergent | field pea (pre-emergent) | field pea - amsinckia,yellow burrweed or burr grass | annual ryegrass | anoda weed | apple-of-peru | awnless barnyard grass | barley grass | barnyard grass or water grass | bathurst burr | bellvine | bifora, carrot weed or bird's eye | bladder ketmia | capeweed | common sida | common thornapple | corn gromwell, ironweed or sheepweed | deadnettle | erodium, crowfoot or storksbill | fat hen | fierce thornapple | green amaranth | hare's-ear or treacle mustard | hyssop loosestrife | indian hedge mustard | ivy leaf speedwell | jute | mintweed | mouse-ear chickweed | noogoora burr | nutgrass | paterson's curse | perennial pigweed | prickly lettuce | redroot or redroot amaranth | shepherd's purse | starburr | stinging or dwarf nettle | three cornered jack or doublegee | three-horned bedstraw | toad rush | turnip weed | wild gooseberry | wild oat | wild radish or radish weed | wireweed, knotweed or hogweed | amsinckia angustifolia | amsinckia calycina | amsinckia hispida | amsinckia intermedia | amsinckia lycopsoides | annual dw

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

imtrade australia pty ltd - sulfometuron-methyl - water dispersible granule - sulfometuron-methyl urea-sulfonyl active 750.0 g/kg - herbicide - agricultural areas - see label | around guide posts | commercial area - general | industrial land or area | rights of way | weed - african lovegrass | annual ryegrass | barnyard or water grass | blue billygoat weed | capeweed | columbus grass | couch | dandelion - hypochaeris glabra | dock | elastic grass | guinea grass | johnson grass | kikuyu grass | long storksbill, corkscrew | paspalum | paterson's curse | phalaris | prairie grass | silver grass or rat's-tail fescue | spear or black thistle | squirrel-tail fescue or silver grass | subterranean clover | summer or crab grass | turnip weed | white clover | wild oat | winter grass | annual blue grass | annual poa | annual summer grass | australian phalaris | barnyard grass | blue top | broadleaf dock | brome fescue | curled dock | echium lycopsis | echium spp. | festuca bromoides | festuca myuros | giant mustard | goose grass | love grass | perennial phalaris | phalaris tuberosa-old si name | purple bugloss | purple viper's bugloss | raphanus rugosum | rapistrum weed | rat's tail fescue | rumex brownii | rumex crispus | rumex obtusifolius | salvation jane | shiny leaf storksbill | short-

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

imtrade australia pty ltd - phosphonic acid - aqueous concentrate - phosphonic acid mineral-phosphorus-acid active 400.0 g/l - fungicide - avocado | citrus - mature (see label for exception | citrus - young or small | grape | ornamental | pineapple | subterranean clo - collar rot - phytophthora cactorum | downy mildew on grape | phytophthora root rot | soil fungi

Australia - English - Department of Health (Therapeutic Goods Administration)

ipca pharma (australia) pty ltd - ciprofloxacin hydrochloride (equivalent: ciprofloxacin, qty mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; colloidal anhydrous silica; macrogol 4000; hypromellose; maize starch; sodium starch glycollate; magnesium stearate; titanium dioxide; purified talc - ciprofloxacin is indicated for treatment of infections caused by susceptible organisms in the conditions listed below: urinary tract infections; gonorrhoeal urethritis and cervicitis; gastroenteritis; bronchial infections; skin and skin structure infections; bone and joint infections; chronic bacterial prostatitis of mild or moderate severity. inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolised bacillus anthracis. ciprofloxacin serum concentrations achieved in humans serve as a surrogate endpoint reasonably likely to predict clinical benefit and provide the basis for this indication. note: 1. typhoid and paratyphoid infections and infections due to multi-resistant staphylococcus aureus are excluded from the above due to insufficient data. 2. because gram-positive organisms are generally less sensitive to ciprofloxacin, it may not be the drug of choice in cases with gram-positive infections, such as pneumonia due to streptococcus pneumoniae. 3. chronic bacterial prostatitis should be demonstrated by microbiological evidence localising infection to the prostate. strains of neisseria gonorrhoea resistant to ciprofloxacin have been reported in australia. appropriate culture and susceptibility tests should be performed before treatment in order to determine organism susceptibility to ciprofloxacin and after treatment as warranted by the clinical condition. therapy with ciprofloxacin may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued. ciprofloxacin is suitable to treat mixed infections caused by susceptible strains of both gram-negative and gram-positive aerobic bacteria. if anaerobic organisms are suspected as accompanying aetiologic agents, additional therapy should be considered.

Australia - English - Department of Health (Therapeutic Goods Administration)

ipca pharma (australia) pty ltd - ciprofloxacin hydrochloride (equivalent: ciprofloxacin, qty 500 mg) - tablet, film coated - excipient ingredients: colloidal anhydrous silica; microcrystalline cellulose; purified talc; hypromellose; macrogol 4000; titanium dioxide; maize starch; sodium starch glycollate; magnesium stearate - ciprofloxacin is indicated for treatment of infections caused by susceptible organisms in the conditions listed below: urinary tract infections; gonorrhoeal urethritis and cervicitis; gastroenteritis; bronchial infections; skin and skin structure infections; bone and joint infections; chronic bacterial prostatitis of mild or moderate severity. inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolised bacillus anthracis. ciprofloxacin serum concentrations achieved in humans serve as a surrogate endpoint reasonably likely to predict clinical benefit and provide the basis for this indication. note: 1. typhoid and paratyphoid infections and infections due to multi-resistant staphylococcus aureus are excluded from the above due to insufficient data. 2. because gram-positive organisms are generally less sensitive to ciprofloxacin, it may not be the drug of choice in cases with gram-positive infections, such as pneumonia due to streptococcus pneumoniae. 3. chronic bacterial prostatitis should be demonstrated by microbiological evidence localising infection to the prostate. strains of neisseria gonorrhoea resistant to ciprofloxacin have been reported in australia. appropriate culture and susceptibility tests should be performed before treatment in order to determine organism susceptibility to ciprofloxacin and after treatment as warranted by the clinical condition. therapy with ciprofloxacin may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued. ciprofloxacin is suitable to treat mixed infections caused by susceptible strains of both gram-negative and gram-positive aerobic bacteria. if anaerobic organisms are suspected as accompanying aetiologic agents, additional therapy should be considered.

Australia - English - Department of Health (Therapeutic Goods Administration)

ipca pharma (australia) pty ltd - ciprofloxacin hydrochloride (equivalent: ciprofloxacin, qty 250 mg) - tablet, film coated - excipient ingredients: colloidal anhydrous silica; maize starch; purified talc; titanium dioxide; sodium starch glycollate; microcrystalline cellulose; magnesium stearate; hypromellose; macrogol 4000 - ciprofloxacin is indicated for treatment of infections caused by susceptible organisms in the conditions listed below: urinary tract infections; gonorrhoeal urethritis and cervicitis; gastroenteritis; bronchial infections; skin and skin structure infections; bone and joint infections; chronic bacterial prostatitis of mild or moderate severity. inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolised bacillus anthracis. ciprofloxacin serum concentrations achieved in humans serve as a surrogate endpoint reasonably likely to predict clinical benefit and provide the basis for this indication. note: 1. typhoid and paratyphoid infections and infections due to multi-resistant staphylococcus aureus are excluded from the above due to insufficient data. 2. because gram-positive organisms are generally less sensitive to ciprofloxacin, it may not be the drug of choice in cases with gram-positive infections, such as pneumonia due to streptococcus pneumoniae. 3. chronic bacterial prostatitis should be demonstrated by microbiological evidence localising infection to the prostate. strains of neisseria gonorrhoea resistant to ciprofloxacin have been reported in australia. appropriate culture and susceptibility tests should be performed before treatment in order to determine organism susceptibility to ciprofloxacin and after treatment as warranted by the clinical condition. therapy with ciprofloxacin may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued. ciprofloxacin is suitable to treat mixed infections caused by susceptible strains of both gram-negative and gram-positive aerobic bacteria. if anaerobic organisms are suspected as accompanying aetiologic agents, additional therapy should be considered.

Australia - English - Department of Health (Therapeutic Goods Administration)

ipca pharma (australia) pty ltd - ciprofloxacin, quantity: 750 mg - tablet, film coated - excipient ingredients: maize starch; microcrystalline cellulose; sodium starch glycollate; colloidal anhydrous silica; magnesium stearate; hypromellose; purified talc; macrogol 4000; titanium dioxide - ciprofloxacin is indicated for treatment of infections caused by susceptible organisms in the conditions listed below: urinary tract infections; gonorrhoeal urethritis and cervicitis; gastroenteritis; bronchial infections; skin and skin structure infections; bone and joint infections; chronic bacterial prostatitis of mild or moderate severity. inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolised bacillus anthracis. ciprofloxacin serum concentrations achieved in humans serve as a surrogate endpoint reasonably likely to predict clinical benefit and provide the basis for this indication. note: 1. typhoid and paratyphoid infections and infections due to multi-resistant staphylococcus aureus are excluded from the above due to insufficient data. 2. because gram-positive organisms are generally less sensitive to ciprofloxacin, it may not be the drug of choice in cases with gram-positive infections, such as pneumonia due to streptococcus pneumoniae. 3. chronic bacterial prostatitis should be demonstrated by microbiological evidence localising infection to the prostate. strains of neisseria gonorrhoea resistant to ciprofloxacin have been reported in australia. appropriate culture and susceptibility tests should be performed before treatment in order to determine organism susceptibility to ciprofloxacin and after treatment as warranted by the clinical condition. therapy with ciprofloxacin may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued. ciprofloxacin is suitable to treat mixed infections caused by susceptible strains of both gram-negative and gram-positive aerobic bacteria. if anaerobic organisms are suspected as accompanying aetiologic agents, additional therapy should be considered.